Insilico Medicine will soon launch an early clinical trial in China to test an inhaled version of its therapy candidate rentosertib in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF). This announcement follows the clearance of the company’s investigational new drug (IND) application by the Chinese Center for…